Earnings Feed
Start Free
Werewolf Therapeutics, Inc.·4

Jun 8, 6:13 PM ET

EVNIN LUKE 4

Research Summary

AI-generated summary

Updated

Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares

What Happened
Luke Evnin, a director of Werewolf Therapeutics (HOWL), sold a total of 105,565 shares in three open‑market transactions executed under a Rule 10b5‑1 plan (dated March 26, 2026). The sales: 20,072 shares on 2026‑06‑04 (weighted avg ~$0.44, ~$8,832), 24,946 shares on 2026‑06‑05 (weighted avg ~$0.40, ~$9,978), and 60,547 shares on 2026‑06‑08 (weighted avg ~$0.40, ~$24,219). Total gross proceeds reported ≈ $43,029. These were sales (transaction code S), not purchases — routine monetization rather than a buy signal.

Key Details

  • Transaction dates & reported weighted average prices:
    • 2026-06-04: 20,072 sh @ $0.44 (proceeds $8,832); sold in multiple trades at $0.43–$0.4499.
    • 2026-06-05: 24,946 sh @ $0.40 (proceeds $9,978); sold in multiple trades at $0.3918–$0.454.
    • 2026-06-08: 60,547 sh @ $0.40 (proceeds $24,219); sold in multiple trades at $0.3706–$0.4126.
  • Shares sold were allocated among related investment entities (per filing): AM LLC, MPM BioVentures 2014 (BV 2014), BV 2014(B), AM BV2014, and MPM Oncology Innovations Fund (MPM OIF). The filing breaks out how many shares each entity sold for each date.
  • Reported holdings (by those entities) are shown in the filing lines associated with the sales (examples listed in the filing include holdings by entity such as AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF).
  • Notable footnotes:
    • Sales were effected pursuant to a 10b5‑1 trading plan (F1).
    • Reported prices are weighted averages; the filing provides price ranges and offers to provide detailed per‑trade prices on request (F3, F7, F10).
    • The filer disclaims beneficial ownership of the securities except to the extent of his pecuniary interest, as the shares are held through the listed investment vehicles (F4).
  • Filing timeliness: the Form 4 was filed 2026‑06‑08 reporting trades from 2026‑06‑04 to 2026‑06‑08. The filing does not indicate a late‑filing flag.

Context
These are outright sales from investment vehicles associated with Luke Evnin, executed under a pre‑existing 10b5‑1 plan. Sales by directors are common for liquidity or portfolio reasons and do not by themselves indicate company performance or insider sentiment. Retail investors tracking insider activity may view purchases as stronger signals than routine sales; here the filing documents disposition and entity allocations rather than option exercises, gifts, or awards.